Gangaraju R, Chen Y, Hageman L, et al. - Researchers focused on the risk of venous thromboembolism (VTE) among patients with non-Hodgkin lymphoma (NHL) who survived 2 years or longer following blood or marrow transplantation (BMT). These patients were observed for a median duration of 8.1 years (interquartile range, 5.6-12.9 years). Among 734 patients with NHL vs 897 siblings without a history of cancer, the risk of VTE was assessed. They also analyzed risk factors related to VTE. Increased risk for VTE was observed in BMT survivors of NHL vs siblings. At 5 years and at 10 years after BMT, the cumulative incidence of VTE was estimated to be 6.3% ± 0.9% and 8.1% ± 1.1%, respectively. An increased risk of VTE was reported in allogeneic BMT recipients in correlation with an increased body mass index and a history of chronic graft-versus-host disease. Increased VTE risk was reported in autologous BMT recipients in correlation with a diagnosis of coronary artery disease and prior treatment with carmustine. Overall, the risk for developing late occurring VTE was found to be present among patients with NHL who survived BMT, and this complication calls for ongoing vigilance.